Last reviewed · How we verify
CodaVax-H1N1
At a glance
| Generic name | CodaVax-H1N1 |
|---|---|
| Sponsor | Codagenix, Inc |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Intramuscular CodaVax-H1N1 in Healthy Adults (PHASE1)
- Safety Study of Live Attenuated Influenza Vaccine, CodaVax, Delivered Via Intranasal Spray (PHASE1)
- Safety Study of Live Attenuated Influenza Vaccine, CodaVax (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CodaVax-H1N1 CI brief — competitive landscape report
- CodaVax-H1N1 updates RSS · CI watch RSS
- Codagenix, Inc portfolio CI